EU patient samples can be performed within the EU territory. EndoPredict and Prolaris must be performed within the EU in our partner laboratories in Greece and Austria.

Other Myriad tests performed in US and are in compliance to In-Vitro Diagnostic Device Directive (98/79/EC) and is CE marked.
Become a partner laboratory in your region.
For more information contact:

EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years)

… to optimize treatment for breast cancer patients.

EndoPredict is a second generation gene expression test – the newest type of test for predicting breast cancer recurrence. It is for post- and premenopausal women with early (non-metastatic) ER+, HER2- breast cancer with or without affected lymph nodes.

EndoPredict accurately measures the activity of specific genes that influence tumor growth, resulting in a 12-Gene Molecular Score. This allows conclusions about the likely outcome of the cancer (prognosis). Higher scores are associated with a higher risk.

EndoPredict patient leaflet_ENG.pdf
EndoPredict_HCP_Premenopausal brochure_ENG.pdf

Prolaris provides new information about your cancer that no other test can. The Prolaris test can determine just how unique and aggressive your prostate cancer truly is. Your Prolaris Score provides individualized information about your specific cancer to help you and your physician develop the appropriate treatment plan.

Prolaris provides answers to your most pressing questions

• What is the risk of my cancer spreading outside of the prostate?

• What is my risk to die from my prostate cancer?

• How should my cancer be treated - Am I a candidate for active surveillance? - Should I consider active treatment?



  • Myriad Genetics’ MyChoice CDx Plus HRD Companion Diagnostic Test is a type of DNA test to reveal if PARP inhibitor treatment is right for you.
    MyChoice CDx Plus provides clear answers to HRD status by giving you either a HRD- or HRD+ result. • HRD- result means you are less likely to benefit from PARP inhibitor treatment. Your doctor will explain your options to you, which may still include going on one PARP inhibitor.
    • HRD+ result means you should benefit from a wider range of PARP inhibitor treatments, and your doctor will discuss which one is best for you.

    The Myriad Genetics MyChoice® CDx Plus test was developed and performance characteristics were determined by Myriad Genetic Laboratories, Inc. and in compliance to In-Vitro Diagnostic Device Directive (98/79/EC) and is CE marked. Myriad is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Myriad is compliant with multiple international standards including, ISO 13485:2016 and ISO 15189: 2012 as applicable.

    MyChoice CDx Plus Patient Brochure_02_22_ENG.pdf

    MyChoice CDx Plus_HCP_Safe decisions brochure_ENG.pdf

  • BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).

    BRACAnalysis CDx® is a CE marked device and has been designed to conform to the applicable standards and the general safety and performance requirements of the European Directive 98/79/EC (in vitro Diagnostic Medical Devices). The declaration of conformity is issued under the responsibility of Myriad Genetic Laboratories, Inc.

    BRACAnalysis CDx (Europe) Technical Specifications.pdf


  • Myriad myRisk® Hereditary Cancer is a 35-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.

    Knowing your patient’s hereditary cancer risk is critical when it comes to making treatment decisions. Blending both genetic test status and personal cancer family history, the MyRisk Hereditary Cancer Panel represents the next generation of hereditary cancer risk testing. MyRisk is here to help you determine the right treatment for your patients with a report including comprehensive results and a guideline-based Medical Management Tool.

    MyRisk Plus HCP Brochure_05_22_EN.pdf

  • RiskScore® is a clinically validated algorithm that predicts a woman’s remaining 5-year and lifetime risk of developing breast cancer at no additional cost (as the additional option for MyRisk test).